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Abstract
Background—Some guidelines advise adjuvant chemotherapy be considered after surgical 
resection for high-risk stage II colon cancer patients; however, high-risk criteria are poorly defined 
and the long-term benefits are still debated. This study documents patterns of care by selected 
patient and tumor characteristics using a US population-based cohort of stage II colon cancer 
patients diagnosed in 2011.
Methods—Data were collected from 10 specialized cancer registries participating in the Centers 
for Disease Control and Prevention’s National Program of Cancer Registries’ Enhancing Cancer 
Registry Data for Comparative Effectiveness Research project. The data were used to describe 
characteristics of stage II colon cancer patients treated by surgery to evaluate factors associated 
with receiving adjuvant chemotherapy.
Results—Of the 3,891 stage II colon cancer patients, 14.3% were treated with surgery and 
adjuvant chemotherapy compared to 82.9% by surgery alone. The patients treated with adjuvant 
chemotherapy were predominately non-Hispanic white (66.1%), of younger age, and had private 
insurance (39.9%). Compared to surgery alone, the 5 characteristics associated with adjuvant 
therapy were younger age (adjusted odds ratio [AOR] for 5-year decrease below 75 years, 1.25; P 
< .001); more advanced stage (IIB/IIC vs IIA) (AOR, 4.79; P < .001); lymphovascular invasion 
(AOR, 1.76, P < .001); higher grade (III/IV vs I/II) (AOR, 1.84; P < .001); and registry area.
Conclusions—In this population-based cohort, younger patients with more advanced stage II 
colon tumors, with lymphovascular invasion, and poor differentiation were more likely to receive 
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adjuvant chemotherapy in addition to surgery. These characteristics align with high-risk profiles 
defined in guidelines. Ongoing data collection on outcomes, including recurrence and survival, 
will help clarify the benefits of adjuvant treatments for stage II colon patients.
Keywords
adjuvant; cancer registries; chemotherapy; colonic neoplasms; National Program of Cancer 
Registries; stage II
Background
In 2012, colon cancer was the fourth leading cause of cancer incidence and mortality in the 
United States, representing 71% of the cancers of large intestine (colon and rectum), with an 
age adjusted incidence rate of 27.8 per 100,000 persons.1 While surgery has been the 
primary curative treatment mode for colon cancer, adjuvant chemotherapy has been shown 
to decrease the risk of recurrence in some patients.2–4 However, early assessments of the 
survival benefits of adjuvant therapy did not support its use for all resected stage II colon 
cancer patients.2,4 The American Society of Clinical Oncology’s (ASCO) guidelines 
indicated in 20043 that clinical trial evidence was insufficient to recommend adjuvant 
chemotherapy but the benefits in stage III patients could be considered in making treatment 
decisions in high-risk stage II patients. Following these recommendations, the benefit of 
adjuvant chemotherapy for stage II cancer cases was assessed in multiple studies5–7 with 
varied conclusions. Based on evidence from randomized clinical trials, Jonker et al argued 
high-risk stage II patients had survival more similar to stage III disease with a 5-year overall 
survival of 40% to 50%.8 However, their resulting conclusions mirrored ASCO’s guidelines 
since the risks of adjuvant chemotherapy are significant and must be weighed against the 
possible benefits.8
Similar to previous recommendations, the National Comprehensive Cancer Network 2016 
treatment guidelines for surgically resected, stage II colon cancer patients include adjuvant 
treatment options ranging from clinical trial recruitment and initiation of standard follow-up 
testing, to considering specific chemotherapies.10 However, the risks related to 
chemotherapy contrasted with the potential for reduced recurrence makes this decision a 
complex one. Therefore, while the identification of high-risk stage II patients is critical 
when determining adjuvant treatment approaches, the definition of what constitutes high risk 
is unclear.9 A number of factors that could place a patient into a high-risk category have 
been suggested; however, a single list of proven prognostic characteristics has not been 
identified. Tumor characteristics studied which may be prognostic include vascular invasion, 
T4 lesion, bowel perforation, inadequately sampled lymph nodes, poor differentiation, bowel 
obstruction, and microsatellite instability;3, 8 those with less evidence include KRAS 
(mutation indicative of poorer survival and no benefit from adjuvant therapy11) and 
carcinoembryonic antigen (CEA).12 Clinical trials have not been able to clearly identify 
specific prognostic factors, in part due to insufficient numbers of patients with these 
characteristics who can be prospectively followed.13
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Prior population-based studies have been limited with respect to geographic and population 
characteristics, including age.14–16 Given the variation in clinical recommendations and the 
lack of precision in defining high-risk stage II colon cancer patients, receipt of adjuvant 
chemotherapy may vary significantly by characteristics of the tumor as well as patient 
characteristics.15 Focusing on stage II colon cancer cases diagnosed in 2011, we evaluated 
the use of adjuvant treatment by tumor and patient characteristics in a population-based 
study that spanned 10 US states and included people of all ages, genders, and races/
ethnicities in these areas.
Methods
Detailed methods of the National Program of Cancer Registries (NPCR) Enhancing Cancer 
Registry Data for Comparative Effectiveness Research (CER) project have previously been 
described.17 In brief, in addition to the North American Association of Central Cancer 
Registries (NAACCR) standard data variables17, 18 that population-based cancer registries 
routinely collect (eg, patient demographics, tumor characteristics, and cancer stage), the 10 
NPCR CER specialized registry areas (including the entire states of Alaska, Colorado, 
Idaho, Louisiana, New Hampshire, North Carolina, Rhode Island and Texas, as well as 13 
counties of the California Sacramento region, and 5 Miami, Florida metro counties) also 
collected expanded patient information. This includes census tract-level socioeconomic 
status, tumor biomarkers, and detailed first course of cancer-directed treatment.17,19
First course of cancer treatment was defined as the therapy regimen that was given or 
planned at the time of initial diagnosis, prior to disease recurrence or progression.19 In 
addition to the routinely collected detailed information on surgery and radiation, the CER 
project also collected complete adjuvant treatment occurring within 12 months of diagnosis. 
The chemotherapy data included each chemotherapy agent’s name and Chemotherapy 
National Service Center (NSC) number, plus start and end dates of chemotherapy by agent.
Data were abstracted from hospital and nonhospital (for example, outpatient and 
independent hematology/oncology practice groups) sources. Cases were followed back to 
treating physician and/or facility to obtain missing information. First course of treatment 
received within 12 months of diagnosis was edited and consolidated so that the data could be 
provided for comparative effectiveness of treatments. All CER areas ran their data through 
the NAACCR Hispanic Identification Algorithm20 and the NAACCR Asian/Pacific Islander 
Identification Algorithm.21 They also participated in linkages with the Indian Health Service 
to improve the quality of their data on race and ethnicity.22
In this study, cases were male and female patients diagnosed in 2011 with colon cancer 
(American Joint Commission on Cancer, 7th edition [AJCC-7] criteria;23 primary site 
C18.0–18.9 and all histologies except 9050–9055, 9140, and 9590–9992) at stage II, 
categorized using the Collaborative Stage AJCC-7 derived stage group variable.24 Data from 
the November 2014 submission to the Centers for Disease Control and Prevention were used 
in this analysis. We excluded patients who died 30 days or less after resection (n = 152), 
were identified only through a death certificate or autopsy report (n = 3), were missing race 
(n = 8), were missing sex or were coded as “other” sex (n = 1), or whose adjuvant 
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chemotherapy was initiated 365 days or more after resection (n = 2), resulting in 3,891 stage 
II colon cancer patients in the analysis.
Frequencies and percentages were calculated for patients’ demographics, tumor, and 
treatment characteristics using SAS 9.3 (SAS Institute). Demographic characteristics 
included: sex, race/ethnicity, age, chronic disease status (using Charlson comorbidity index 
comorbidities,25 which were grouped into 3 categories: non-Charlson comorbidity, 1 
Charlson comorbidity or 2 or more Charlson comorbidities; those who were coded as having 
no comorbidity were set to unknown, as this category could have included both individuals 
having no comorbid conditions and situations where there was no mention of comorbidity in 
the medical record), insurance payer, and US census tract level measures of family poverty 
status and urbanization. Census tracts were created by geocoding patient’s residence at the 
time of diagnosis and linking case data with Census Bureau census tract level 
socioeconomic indicators, including family poverty level (percent of families below Federal 
poverty level) and urbanization (100% urban setting, 100% rural setting, and mixed urban 
and rural settings).17 Tumor characteristics were stage category (IIA, IIB, or IIC based on 
whether the primary tumor is classified as T3, T4a, or T4b, respectively17), grade, number of 
nodes examined (total number of regional lymph nodes that were removed and examined by 
a pathologist), and lymphatic and/or vascular invasion (as reported in the pathology report). 
Treatment was categorized as surgery-only or surgery plus adjuvant chemotherapy, based on 
dates of surgery and start date of chemotherapy and a valid NSC chemotherapy agent for 
treating colon cancer.
Statistically significant (P < .05) characteristics associated with patients receiving adjuvant 
chemotherapy in addition to surgical resection were assessed using logistic regression. Due 
to a high percentage of missing comorbidity data, a multivariate analysis was conducted 
using multiple imputations for missing data. The imputation was conducted using R (3.14–
5)26 software, Hmisc27 package’s aregImpute function. This method consists of multiple 
imputations using predictive mean matching. Ultimately, the imputed data were not used 
because characteristics associated with patients receiving adjuvant chemotherapy did not 
differ and also the significance level of association in the models using imputed and non-
imputed data did not differ greatly. Furthermore, comorbidity was not significant after 
adjusting for other covariates and was excluded from the final model.
The final model was developed using backward elimination variable selection. The linearity 
assumption for the continuous age variable was tested using restricted cubic spline 
functions28 and it was found to be nonlinear. The age variable was transformed in the final 
model using a linear spline. Age was split into 2 linear segments at age 75 and the odds 
ratios for this continuous variable are presented for 5-year increments. Additional 
information on restricted cubic spline regression and transforming independent variables is 
available at http://support.sas.com/resources/papers/proceedings16/5621-2016.pdf (Croxford 
R. Restricted cubic spline regression: a brief introduction. SAS Paper 5621-2016). Cases 
missing adjuvant chemotherapy information (n = 110) were excluded from the final model. 
Patient’s sex and race/ethnicity were controlled for in the final model, although they were 
not significant. Modeling was conducted in R (version 3.1.1).27
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Results
Of the 3,891 stage II colon cancer patients diagnosed in the 10 specialized registry areas, 
14.3% (n = 557) were treated with adjuvant chemotherapy following surgery and 82.9% (n = 
3,224) were treated with surgery alone (Table 1). The percent distributions of sex between 
the treatment groups were similar; 52.0% of the surgery alone and 51.2% of the surgery plus 
adjuvant patients were women. The distribution of race/ethnicity for surgery-only patients 
and surgery plus adjuvant patients was 70.1% vs 66.1% non-Hispanic white, 12.2% vs 
14.4% non-Hispanic black, and 14.6% vs 16.3% Hispanic (Table 1). The patients who were 
treated with adjuvant chemotherapy were younger (median age: 60.9 years) compared to 
surgery-only patients (median age: 70.7 years). Correspondingly, there was a higher percent 
of patients with 2 or more Charlson comorbidity conditions among the surgery-only patients 
compared to those receiving adjuvant therapy (10.6% vs 5.9%, respectively). A larger 
proportion of surgery-only patients were covered by Medicare alone (44.6%) than those 
treated with surgery and adjuvant chemotherapy (28.0%) (Table 1).
The 2 treatment groups were similar in sociodemographic characteristics. The census level 
assessment of poverty (ie, patients who lived in a census tract where ≥20% of families had 
incomes below the Federal poverty line in the last 12 months) for surgery-only patients and 
surgery plus adjuvant patients was 17.4% and 14.2%, respectively. Also, the percent of 
surgery-only patients living in a 100% urban census tract, as defined by the US Census, was 
58.9% and 52.4% for patients also receiving adjuvant chemotherapy (Table 1).
There were differences in the tumor characteristics of the 2 treatment groups. These included 
stage: the surgery-only patients had a higher frequency of stage IIA (89.5%) than the 
patients treated with surgery and adjuvant chemotherapy (65.7%). Surgery-only patients also 
had a lower frequency of grade III cancer (14.0%) compared to patients treated with 
adjuvant chemotherapy (21.5%); and lymphovascular invasion was present less frequently 
among surgery-only patients (11.3%) than patients treated with surgery and adjuvant 
chemotherapy (20.8%). However, the 2 groups were similar in regards to the number of 
nodes examined: 85.2% and 85.1% of the surgery-only patients and surgery plus adjuvant 
therapy patients, respectively, had 12 or more nodes examined (Table 1).
Table 2 shows the 5 characteristics associated with a patient being treated by surgery and 
adjuvant chemotherapy: younger age (in age segment below 75 years, every 5-year decrease 
was associated with an adjusted odds ratio [AOR] of 1.25; 95% CI, 1.18–1.31; and for age 
segment above 75 years, every 5-year decrease was associated with AOR of 2.80; 95% CI, 
2.12–3.68); higher stage (AOR comparing IIB/IIC to IIA, 4.79; 95% CI, 3.71–6.17); higher 
tumor grade (AOR comparing Grade High III/IV vs Low I/II, 1.84; 95% CI, 1.41–2.40); the 
presence of lymphovascular invasion (AOR comparing invasion to no invasion, 1.76; 95% 
CI, 1.34–2.31); and registry area (for example, AOR comparing North Carolina to Texas, 
1.54; 95% CI, 1.12–2.11 and AOR comparing Rhode Island to Texas, 2.61; 95% CI, 1.37–
4.98).
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Discussion
For patients with surgically resected stage II colon cancer, adjuvant chemotherapy is not 
always beneficial29 or routinely recommended. Identification of characteristics that indicate 
a higher risk of recurrence or progression is important in avoiding the risks associated with 
chemotherapy in patients who are not likely to benefit.3,8 We examined the use of adjuvant 
therapy in a population-based study utilizing data from 10 population-based cancer registries 
which collected expanded data for colorectal cancer patients diagnosed in 2011. The 
inclusion of all stage II colon cancer patients allows an unbiased examination to the use of 
adjuvant chemotherapy in this study population.
Only 14.3% of stage II colon cancer patients in our study were treated with adjuvant 
chemotherapy after surgery. Those treated with adjuvant chemotherapy tended to be younger 
(median age, 60.9 years) than those treated with surgery alone (median age, 70.7 years). 
There was a nonlinear relationship between chemotherapy and age. When age was modeled 
as 2 linear segments, we found that, among patients younger than 75 years, those 5 years 
younger had 1.25 times the odds of receiving surgery and adjuvant chemotherapy compared 
to someone 5 years older. Among patients older than 75 years, the effect was larger: 
someone 5 years younger had 2.80 times the odds of receiving surgery and adjuvant 
chemotherapy than an individual 5 years their senior.
Adjuvant chemotherapy was more frequently used in patients whose cancer was a stage IIB 
or IIC and somewhat more common for those with a high grade tumor or lymphovascular 
invasion. Having 2 or more Charlson comorbidities and Medicare-only insurance was more 
common among those with surgery alone. We did find geographic differences in treatment 
patterns (specifically, more adjuvant chemotherapy in Idaho, Louisiana, North Carolina and 
Rhode Island); however, we did not detect an obvious regional effect. Our statistical 
modeling included race and ethnicity in addition to demographics: insurance status, urban/
rural residence, Charlson comorbidities, and poverty status based on census tracts. In the 
final model, the factors significantly associated with receiving adjuvant therapy following 
surgery were: younger age, stage (IIB/IIC vs IIA), grade (high vs low); lymphovascular 
invasion (presence vs absence) and registry area. More advanced stage of disease (stage 
IIB/C) was the strongest indicator for adjuvant therapy with an adjusted odds ratio of 4.79 
(3.71–6.17) when compared to stage IIA patients.
While our study provides population-based data, there were limitations with respect to the 
analysis. Because cancer registry data are based on clinically-relevant data available in the 
medical chart and some factors known to influence patterns of care are not routinely and 
consistently captured in clinical documentation, we were unable to examine some variables 
of interest such as patient’s preference. We were not able to examine individual level 
measures of poverty or “urbanicity” and instead used area-based measures. We also did not 
have needed detail to explore the differences identified among the registry areas. With 
respect to high-risk tumor characteristics, we were not able to examine colon obstruction or 
microsatellite instability, which may have influenced treatment decisions13 (the project did 
not collect data on colon obstruction and, while microsatellite instability was collected, the 
number of missing values was too high to allow for inclusion in the analyses). Though 
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information on comorbidities was collected from medical charts and data linkages for this 
study, we could not discern between those instances where no comorbidities existed and 
when data were missing. Consequently, a large proportion of the comorbidity information 
was treated as missing. There were indications in the modeling that those with 2 or more 
Charlson comorbidities were less likely to receive adjuvant chemotherapy; however, 
multiple imputation was used to impute missing comorbidity data and comorbidities overall 
were not significant in the final model. The presence of comorbid conditions has been shown 
to be associated with less aggressive treatment in other population-based studies.15,30,31
Increasing age is often associated with the presence of comorbid conditions and both are 
related to cancer survival.32 The relationship between age, comorbidity, and cancer is a 
complex, influencing the risk of cancer occurrence, treatment, and outcomes.29,33,34 In our 
study, increasing age was significantly associated with less aggressive treatment, but we 
were not able to fully explore the possible confounding relationship between age and 
comorbidities. However, a meta-analysis of treatment in colorectal cancer patients of all 
stages indicated that older patients in good health otherwise had survival benefits from the 
use of chemotherapy.32 Health insurance status has been found to influence many aspects of 
cancer care35; however, it is also strongly correlated with age because of the eligibility 
criteria for Medicare coverage. Because of this collinearity, insurance was removed from the 
final model for our study.
Conclusions
Within the 10 geographic areas included in this study, surgery is often used alone for stage II 
colon cancer patients, particularly for stage IIA. In addition, in most, though certainly not all 
cases, adjuvant therapy was focused on patients with the higher risk characteristics that had 
been identified in practice-based guidelines at the time that treatment decisions were made. 
These findings correspond with guideline recommendations that adjuvant chemotherapy 
should not be routinely administered and physicians consider discussing the option with 
patients who are at risk of recurrence.3,10,13 Given the variation in the characteristics of the 
states and regions included in this study, the surgical and chemotherapy practices are likely 
similar to those that would be found throughout the United States. Our study included all 
ages, genders, races, and income levels which can only be accomplished through a large 
population-based cohort. This population is being followed and data collected on recurrence, 
progression, and mortality. Subsequent comparative effectiveness analyses based on these 
data will provide population-based assessments of survival outcomes among these patients.
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